Report Detail
Covid-19 Impact on Immuno-oncology Drugs Market, Global Research Reports 2020-2021
- RnM3971489 |
- 18 May, 2020 |
- Global |
- 100 Pages |
- QYResearch |
- Pharma & Healthcare
This report covers market size and forecasts of Immuno-oncology Drugs, including the following market information:
Global Immuno-oncology Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Immuno-oncology Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Immuno-oncology Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Immuno-oncology Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)
Key market players
Major competitors identified in this market include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Based on the Application:
Hospitals
Pharmacies
Online Pharmacies
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Immuno-oncology Drugs Quarterly Market Size Analysis
- 2.1 Immuno-oncology Drugs Business Impact Assessment - COVID-19
- 2.1.1 Global Immuno-oncology Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Immuno-oncology Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Immuno-oncology Drugs Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 Global Immuno-oncology Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Immuno-oncology Drugs Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Immuno-oncology Drugs Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Immuno-oncology Drugs Market
- 3.5 Key Manufacturers Immuno-oncology Drugs Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Immuno-oncology Drugs Segments, By Type
- 4.1 Introduction
- 1.4.1 Immune Checkpoint Inhibitors
- 1.4.2 Monoclonal Antibodies
- 1.4.3 Cytokine-Based Immunotherapy
- 1.4.4 Cancer Vaccines
- 1.4.5 CAR-T Cell Therapy
- 4.2 By Type, Global Immuno-oncology Drugs Market Size, 2019-2021
- 4.2.1 By Type, Global Immuno-oncology Drugs Market Size by Type, 2020-2021
- 4.2.2 By Type, Global Immuno-oncology Drugs Price, 2020-2021
5 Impact of Covid-19 on Immuno-oncology Drugs Segments, By Application
- 5.1 Overview
- 5.5.1 Hospitals
- 5.5.2 Pharmacies
- 5.5.3 Online Pharmacies
- 5.2 By Application, Global Immuno-oncology Drugs Market Size, 2019-2021
- 5.2.1 By Application, Global Immuno-oncology Drugs Market Size by Application, 2019-2021
- 5.2.2 By Application, Global Immuno-oncology Drugs Price, 2020-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Amgen, Inc
- 7.1.1 Amgen, Inc Business Overview
- 7.1.2 Amgen, Inc Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.1.3 Amgen, Inc Immuno-oncology Drugs Product Introduction
- 7.1.4 Amgen, Inc Response to COVID-19 and Related Developments
- 7.2 AstraZeneca, Plc
- 7.2.1 AstraZeneca, Plc Business Overview
- 7.2.2 AstraZeneca, Plc Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Product Introduction
- 7.2.4 AstraZeneca, Plc Response to COVID-19 and Related Developments
- 7.3 Bristol-Myers Squibb
- 7.3.1 Bristol-Myers Squibb Business Overview
- 7.3.2 Bristol-Myers Squibb Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Product Introduction
- 7.3.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
- 7.4 Celgene Corporation
- 7.4.1 Celgene Corporation Business Overview
- 7.4.2 Celgene Corporation Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.4.3 Celgene Corporation Immuno-oncology Drugs Product Introduction
- 7.4.4 Celgene Corporation Response to COVID-19 and Related Developments
- 7.5 Eli Lilly and Company
- 7.5.1 Eli Lilly and Company Business Overview
- 7.5.2 Eli Lilly and Company Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.5.3 Eli Lilly and Company Immuno-oncology Drugs Product Introduction
- 7.5.4 Eli Lilly and Company Response to COVID-19 and Related Developments
- 7.6 Merck & Co.
- 7.6.1 Merck & Co. Business Overview
- 7.6.2 Merck & Co. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.6.3 Merck & Co. Immuno-oncology Drugs Product Introduction
- 7.6.4 Merck & Co. Response to COVID-19 and Related Developments
- 7.7 Hoffmann-La Roche AG
- 7.7.1 Hoffmann-La Roche AG Business Overview
- 7.7.2 Hoffmann-La Roche AG Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product Introduction
- 7.7.4 Hoffmann-La Roche AG Response to COVID-19 and Related Developments
- 7.8 Johnson & Johnson
- 7.8.1 Johnson & Johnson Business Overview
- 7.8.2 Johnson & Johnson Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.8.3 Johnson & Johnson Immuno-oncology Drugs Product Introduction
- 7.8.4 Johnson & Johnson Response to COVID-19 and Related Developments
- 7.9 Novartis International AG
- 7.9.1 Novartis International AG Business Overview
- 7.9.2 Novartis International AG Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.9.3 Novartis International AG Immuno-oncology Drugs Product Introduction
- 7.9.4 Novartis International AG Response to COVID-19 and Related Developments
- 7.10 AbbVie, Inc.
- 7.10.1 AbbVie, Inc. Business Overview
- 7.10.2 AbbVie, Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.10.3 AbbVie, Inc. Immuno-oncology Drugs Product Introduction
- 7.10.4 AbbVie, Inc. Response to COVID-19 and Related Developments
- 7.11 Pfizer Inc.
- 7.11.1 Pfizer Inc. Business Overview
- 7.11.2 Pfizer Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.11.3 Pfizer Inc. Immuno-oncology Drugs Product Introduction
- 7.11.4 Pfizer Inc. Response to COVID-19 and Related Developments
- 7.12 Sanofi S.A.
- 7.12.1 Sanofi S.A. Business Overview
- 7.12.2 Sanofi S.A. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.12.3 Sanofi S.A. Immuno-oncology Drugs Product Introduction
- 7.12.4 Sanofi S.A. Response to COVID-19 and Related Developments
- 7.13 EMD Serono, Inc.
- 7.13.1 EMD Serono, Inc. Business Overview
- 7.13.2 EMD Serono, Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Product Introduction
- 7.13.4 EMD Serono, Inc. Response to COVID-19 and Related Developments
- 7.14 Gilead Sciences Inc.
- 7.14.1 Gilead Sciences Inc. Business Overview
- 7.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Product Introduction
- 7.14.4 Gilead Sciences Inc. Response to COVID-19 and Related Developments
- 7.15 Prometheus Therapeutics & Diagnostics
- 7.15.1 Prometheus Therapeutics & Diagnostics Business Overview
- 7.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Introduction
- 7.15.4 Prometheus Therapeutics & Diagnostics Response to COVID-19 and Related Developments
- 7.16 Aduro BioTech
- 7.16.1 Aduro BioTech Business Overview
- 7.16.2 Aduro BioTech Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.16.3 Aduro BioTech Immuno-oncology Drugs Product Introduction
- 7.16.4 Aduro BioTech Response to COVID-19 and Related Developments
- 7.17 Galena Biopharma
- 7.17.1 Galena Biopharma Business Overview
- 7.17.2 Galena Biopharma Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.17.3 Galena Biopharma Immuno-oncology Drugs Product Introduction
- 7.17.4 Galena Biopharma Response to COVID-19 and Related Developments
- 7.18 Bavarian Nordic
- 7.18.1 Bavarian Nordic Business Overview
- 7.18.2 Bavarian Nordic Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.18.3 Bavarian Nordic Immuno-oncology Drugs Product Introduction
- 7.18.4 Bavarian Nordic Response to COVID-19 and Related Developments
- 7.19 Celldex Therapeutics
- 7.19.1 Celldex Therapeutics Business Overview
- 7.19.2 Celldex Therapeutics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.19.3 Celldex Therapeutics Immuno-oncology Drugs Product Introduction
- 7.19.4 Celldex Therapeutics Response to COVID-19 and Related Developments
- 7.20 ImmunoCellular Therapeutics
- 7.20.1 ImmunoCellular Therapeutics Business Overview
- 7.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Introduction
- 7.20.4 ImmunoCellular Therapeutics Response to COVID-19 and Related Developments
- 7.21 Incyte
- 7.21.1 Incyte Business Overview
- 7.21.2 Incyte Immuno-oncology Drugs Quarterly Production and Revenue, 2020
- 7.21.3 Incyte Immuno-oncology Drugs Product Introduction
- 7.21.4 Incyte Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
- 8.1 Immuno-oncology Drugs Supply Chain Analysis
- 8.1.1 Immuno-oncology Drugs Supply Chain Analysis
- 8.1.2 Covid-19 Impact on Immuno-oncology Drugs Supply Chain
- 8.2 Distribution Channels Analysis
- 8.2.1 Immuno-oncology Drugs Distribution Channels
- 8.2.2 Covid-19 Impact on Immuno-oncology Drugs Distribution Channels
- 8.2.3 Immuno-oncology Drugs Distributors
- 8.3 Immuno-oncology Drugs Customers
9 Key Findings
10 Appendix
- 10.1 About Us
Summary:
Get latest Market Research Reports on Covid-19 Impact on Immuno-oncology Drugs. Industry analysis & Market Report on Covid-19 Impact on Immuno-oncology Drugs is a syndicated market report, published as Covid-19 Impact on Immuno-oncology Drugs Market, Global Research Reports 2020-2021. It is complete Research Study and Industry Analysis of Covid-19 Impact on Immuno-oncology Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
